A special focus on the vaccine industry.  
MarketVIEW - Pseudomonas aeruginosa vaccines

Updated: Jan 2011

Gram-positive Pseudomonas aeruginosa (PA) is primarily a nosocomial pathogen accounting for around 10% of all hospital acquired infections second only to Staphylococcus aureus . PA infections are invasive and toxigenic and affect a wide variety of patient groups but mainly those with lung dysfunction such as pneumonia (ICU), COPD and Cystic fibrosis. Other important risk groups are severe burns patients. Although PA infections are treatable, many forms of PA are multidrug resistant (MDR) and associated with high mortality. Despite previous failures of developmental prophylactic vaccines to prevent PA infections vaccine companies are now investigating newer strategies with the most advanced vaccine now in Phase II testing.

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for all products within target nosocomial and lung disease populations until 2030. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on nosocomial vaccines.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV010 Click here>>
Discounted option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2011 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains